폐기종 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global emphysema treatment market size is expected to reach USD 10.12 Billion in 2034 from USD 5.65 Billion in 2025, growing at a CAGR of 6.7 during 2026-2034.This market is witnessing significant growth due to the rising prevalence of chronic respiratory diseases and increasing awareness regarding early diagnosis and treatment. Emphysema, a major form of chronic obstructive pulmonary disease, continues to affect millions of individuals worldwide. Growing healthcare expenditures and advancements in respiratory care are supporting market expansion and improving treatment accessibility.

Increasing smoking rates in some regions, environmental pollution, and aging populations are key factors contributing to disease prevalence and treatment demand. Pharmaceutical companies are investing heavily in research and development to introduce more effective therapies and improve patient outcomes. Enhanced diagnostic technologies and greater awareness campaigns are encouraging earlier intervention, which is positively influencing market growth.

Future prospects appear promising as innovative treatment approaches and personalized medicine continue to evolve. Advancements in biologics, regenerative therapies, and minimally invasive procedures may transform disease management. Expanding healthcare infrastructure in developing economies is expected to improve patient access to treatment. Continued investment in respiratory disease research will likely create substantial growth opportunities for market participants.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment

• Smoking Cessation
• Bronchodilators
• Steroids
• Leukotriene Modifiers
• Supplemental Oxygen
• Antibiotics
• Gene Therapy
• Surgery Transplant
• Other

By Distribution Channel

• Online Providers
• Drug Stores and Retail Pharmacies
• Hospital Pharmacies

By End-User

• Clinics
• Surgical Centre
• Others

COMPANIES PROFILED

• AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Bioxyne Limited, Intrexon Corporation, iCure Pharmaceuticals Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL EMPHYSEMA TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. Smoking Cessation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Bronchodilators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Steroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Leukotriene Modifiers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Supplemental Oxygen Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Antibiotics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Surgery Transplant Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL EMPHYSEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Online Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Drug Stores and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL EMPHYSEMA TREATMENT MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Surgical Centre Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL EMPHYSEMA TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Treatment
  • 7.2.2 By Distribution Channel
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Treatment
  • 7.3.2 By Distribution Channel
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Treatment
  • 7.4.2 By Distribution Channel
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Treatment
  • 7.5.2 By Distribution Channel
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Treatment
  • 7.6.2 By Distribution Channel
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL EMPHYSEMA TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AstraZeneca PLC
  • 9.2.2 Teva Pharmaceutical Industries Ltd
  • 9.2.3 Novartis AG
  • 9.2.4 GlaxoSmithKline PLC
  • 9.2.5 Hikma Pharmaceuticals PLC
  • 9.2.6 Boehringer Ingelheim GmbH
  • 9.2.7 Mylan N.V
  • 9.2.8 Pfizer Inc
  • 9.2.9 Orion Oyj
  • 9.2.10 Verona Pharma PLC
  • 9.2.11 Pulmonx Corporation
  • 9.2.12 Bioxyne Limited
  • 9.2.13 Intrexon Corporation
  • 9.2.14 ICure Pharmaceuticals Inc